Sep. 10, 2009 (Business Wire) Pluristem Begins Enrollment in U.S. in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease.

Nov 17, 2009,•HAIFA, Israel--(BUSINESS WIRE)--Three Month Follow-Up Data from the First Patient to Receive PLX-PAD.

6-28-10, Pluristem is Advancing Toward Two Phase IIb Clinical Trials for Treatment of Critical Limb Ischemia and Moderate-Severe Claudication.

HAIFA, ISRAEL, January 18, 2011 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE:PLTR), today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company’s planned clinical development program for PLX-PAD.

e